Aptima® Sexual and Vaginal Health Solutions Test
The most comprehensive sexual and vaginal health molecular menu.
Hologic offers the most comprehensive sexual and vaginal health portfolio that allows you to automate molecular testing workflows while instilling confidence in your clinical results.
One Sample, Multiple Results
With innovative nucleic acid amplification test (NAAT) and a single collection device, the Aptima® Multitest Swab simplifies testing by helping to detect up to 7 infections and disease states from just 1 vaginal swab.1-5
Expert Partner
Through continuous clinical research and trusted testing solutions, Hologic supports our partners in the fight against sexually transmitted infections (STIs) and accurate detection of vaginitis.
Proven Performance
Our sexual and vaginal health portfolio leverages best-in-class technology to provide timely and reliable results to patients.
Streamlined Workflow
The Aptima sexual and vaginal health portfolio can run alongside multiple disease areas on our fully automated Panther® Scalable Solutions.
Evolve Your Offerings with Aptima Assays
7 infections and disease states
can be detected with the Aptima sexual and vaginal health portfolio to support your testing needs.
35 years of experience
in sexual and vaginal health molecular testing and helping stop the spread of disease.
Increasing Certainty in Sexual & Vaginal Health
The Aptima sexual and vaginal health portfolio represents a comprehensive menu to champion women’s health worldwide. By supporting sexual health testing with innovative technology and a fully automated, sample-to-result platform, we are helping advance early detection and treatment.
Hologic is committed to protecting sexual and reproductive health by preventing the spread of STIs and vaginitis. We are continuously investing in R&D efforts designed to deliver new products to help healthcare providers and laboratories provide better patient care, now and in the future.
The Significance of Diagnostic Testing in Women’s Health: Mycoplasma genitalium
Dr. Kyle Bukowski*, Chief Medical Officer for Planned Parenthood of Maryland, discusses real-world data reflective of current practices in the U.S. for Mycoplasma genitalium.
Timeline
*The Aptima Zika Virus assay: This test has not been FDA cleared or approved; This test has been authorized by FDA under an EUA for use by authorized laboratories; This test has been authorized only for the detection of RNA from Zika virus and diagnosis of Zika virus infection, not for any other viruses or pathogens; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C.§ 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
† Speaker and consultant for Hologic, Inc.
References: 1. Aptima Combo 2 Assay [package insert]. AW-20535, San Diego,CA; Hologic, Inc., 2022. 2. Aptima Mycoplasma genitalium assay [package insert]. AW-17946, San Diego, CA; Hologic, Inc., 2019. 3. Aptima CV/TV assay [package insert]. AW-18812, San Diego, CA;Hologic, Inc., 2021 4. Aptima BV assay [package insert]. AW-18811, San Diego, CA; Hologic, Inc., 2020. 5. Aptima Trichomonas vaginalis Assay [package insert]. 503684, San Diego, CA; Hologic, Inc., 2020. 6. Aptima HSV 1 & 2 assay [package insert]. AW-15346-001, San Diego, CA; Hologic, Inc., 2019. 7. CDC. Incidence, Prevalence, and Cost of Sexually Transmitted Infection in the United States. Last reviewed: March 16, 2022. Accessed July 7, 2022. https://www.cdc.gov/nchhstp/newsroom/fact-sheets/std/STI-Incidence-Prevalence-Cost-Factsheet.html [cdc.gov]. 8. Aptima Zika virus assay [package insert]. AW-15406, San Diego, CA; Hologic, Inc., 2018.
